Kiora Pharmaceuticals appointed Keith Lane to lead clinical development and regulatory affairs, with a $350,000 salary and an option for 55,000 shares. The appointment matters because Lane’s ophthalmology development experience is intended to support the company’s pipeline and new asset opportunities, alongside a $75,000 sign-on Bonus and performance target of up to 35%.
Key Highlights
- Keith Lane will receive a $75,000 sign-on bonus under his employment terms.
- His performance bonus carries a target of up to 35% of annual base salary.
- Lane previously held senior clinical and scientific roles at ophthalmology-focused Ora.
KIORA PHARMACEUTICALS INC (NASDAQ: KPRX) appointed Keith Lane as executive vice president and head of clinical development and regulatory affairs, effective September 8, 2026. The role carries an annual base salary of $350,000, and Lane will serve as the company’s principal clinical development executive.
$350,000 Salary and 55,000-Share Option
The employment arrangement is at will, and the offer letter was entered into on June 22, 2026.
Clinical Experience Supports Kiora Pipeline
Lane previously served as chief scientific officer at Ora, an ophthalmology-focused clinical research organization, after holding senior clinical and therapeutic-area positions there. Kiora’s press release stated that his experience would support advancement of its pipeline and new asset opportunities. Lane will report to Chief Executive Officer Brian Strem.
FAQs
Q: What salary will Keith Lane receive from Kiora Pharmaceuticals?
A: Keith Lane will receive an annual base salary of $350,000 in his role as Kiora Pharmaceuticals’ executive vice president and head of clinical development and regulatory affairs. The appointment became effective September 8, 2026.
Q: What bonus package is included in Keith Lane’s appointment?
A: His offer letter provides a $75,000 sign-on bonus and eligibility for a discretionary annual performance bonus targeted at up to 35% of annual base salary. The sign-on bonus is subject to repayment in specified circumstances.
Q: What equity award is included in Keith Lane’s employment terms?
A: Subject to Compensation Committee approval and issuance under Kiora’s 2024 Equity Incentive Plan, Lane will receive an option covering up to 55,000 common shares. One-third vests after one year, with monthly vesting thereafter.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.